Related Experiment Video
Updated: Sep 13, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
Toward Personalized Decision Support Systems for Type 1 Diabetes: Integrating Psychobehavioral Factors and Glycemic
Mohammadreza Ganji1, Leela Krishna Chaitanya Koravi1, Marc Breton1
1Center for Diabetes Technology, University of Virginia, Charlottesville, VA, USA.
Journal of Diabetes Science and Technology
|August 4, 2025
Summary
This study introduces a new framework for technology in type 1 diabetes (T1D) management that considers patient preferences. It aims to improve glycemic control and quality of life by personalizing therapeutic advice delivery.
Area of Science:
- Biomedical Engineering
- Digital Health
- Diabetes Technology
Background:
- Current type 1 diabetes (T1D) technologies often neglect psychobehavioral factors like individual preferences and goals.
- This limits the effectiveness of glucose-centric management tools.
Purpose of the Study:
- To present a framework for developing T1D management technology that integrates psychobehavioral factors.
- To design an algorithm that incorporates user preferences into therapeutic advice delivery.
Main Methods:
- Developed a decision support system (DSS) offering therapeutic advice for T1D management.
- The DSS features "prescriptive" and "informative" modes to cater to user preferences.
- A randomized crossover trial will evaluate the DSS using continuous glucose monitoring and psychometric assessments.
Main Results:
- The study outlines a novel framework for personalized DSS technology in T1D.
- The DSS is designed to adapt therapeutic insight delivery based on user preferences.
Conclusions:
- This work advances user-centric technology for T1D by integrating psychobehavioral factors.
- The goal is to enhance clinical outcomes and improve patients' quality of life.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
386
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
386
01:22Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
01:22Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K
01:16Insulin: Dosing Regimen and Adverse Effects
262
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
262
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
298
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
298
01:36Carbohydrate Metabolism
11.7K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.7K